Comparison of data from WBE with other sources

Slides:



Advertisements
Similar presentations
REPORT Full report Executive summary Methodology STATISTICAL ANNEX Seizures Drug use Prices Illicit laboratories.
Advertisements

What can Europe learn from the US experience of policy-related drugs monitoring? Terry Zobeck, Ph.D. Office of National Drug Control Policy Executive Office.
Jelle van Minnen 20 June EPA IG Climate & Adaptation.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
Wayne Hall Centre for Youth Substance Abuse Research University of Queensland Centre and National Addiction Centre Kings College London Testing the Waters:
National Prescription Drug Threat Assessment 2009 National Drug Intelligence Center Drug Enforcement Administration.
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Heavy or problematic drug use, heavy and problematic to define? Iceland August 2010, Nordic Alcohol and Drug Researchers’ Assembly Ellen J. Amundsen,
The development of an Australian drug policy index Assoc Prof Alison Ritter Director, Drug Policy Modelling Program (DPMP) University of New South Wales.
Drug-related deaths in England: latest data Martin White, Alcohol, Drugs and Tobacco Division, Public Health England.
Problem drug use, HIV and injecting: an overview of the European experience Paul Griffiths, EMCDDA Drug Control in the Baltic Region, Vilnius, 27 September.
Monitoring drug related overdose and mortality in Europe Dr. Eva Keller.
Overview of the 2010 work programme Paul Griffiths, Roland Simon, Rosemary de Sousa Scientific Committee meeting, Lisbon, November 2009.
Strenghtening collaboration with Serbia - IPA4 Project expected outcomes Frédéric Denecker, Programme Management Officer Reitox and International Cooperation.
Drug Trends in Washington State & King County Caleb J. Banta-Green MPH MSW Alcohol & Drug Abuse Institute University of Washington
Substance Use and Recessions: Insights from Economic Analyses of Alcohol and Drug Use Rosalie Liccardo Pacula, Ph.D. Co-Director RAND Drug Policy Research.
Advanced Briefing to Member States
ARQ part II data management Training pack 1: Content and conceptual issues.
Major findings from the 2013 World Drug Report. Drug use Overall drug use, including problem drug use, has remained largely stable over the past 5 years.
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
ESPAD – are young Europeans getting more alike? Björn Hibell EMCDDA Conference Identifying Europe's Information needs for effective drug.
Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Treatment system-based data collection: an integrated approach to monitoring Expert meeting: Implementation of the treatment strategy EMCDDA Lisbon,
Polydrug use challenges – European experience International Conference: New trends in drug use: facts and solutions, Parliament of the Republic of Vilnius.
Annual report 2010: the state of the drugs problem in Europe.
Annual report 2009: the state of the drugs problem in Europe International Conference: New trends in drug use: facts and solutions, Parliament of the Republic.
Trends and developments Selected trends and some insights in prevention Vilnius, 12 November 2014 Roland Simon.
November TRB 2012 DRUID session Drug Driving Enforcement Marjan Hagenzieker and Sjoerd Houwing
Annual report 2009: the state of the drugs problem in Europe NB Embargo 5 November :00 CET (Brussels time)
An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.
Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.
Epidemiology of addictive disorders: a brief review MRCPsych addiction psychiatry seminar series Dr Stuart McLaren 2 nd March 2012.
Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.
Background information about ESPAD The European School Survey Project on Alcohol and Other Drugs.
Annual report 2012: the state of the drugs problem in Europe Name, date.
Overview of the cannabis use in Europe Paul Griffiths, Reitox academy, Berlin, 29th March 2007.
EXPOSURE TO TOBACCO SMOKE IN THE EUROPEAN UNION 2nd Working Meeting on Adult Premature Mortality in the European Union October 2006, Warsaw, Poland.
Alcohol and Drug Problem in Poland. Implications for policy Janusz Sierosławski Institute of Psychiatry i Neurology 3rd Meeting of the Expert Group on.
A Search For Better Health Topic 11: Epidemiology
Jekaterina Dobrijana Senior Officer on Addiction Surveillance
Drug Trends in Sweden 2017 Figures 1–
World Drug Report 2011.
A “Scottish effect” for health?
Establishment of NGO info points for NPS sample collection within regional EWS in the framework of I-SEE project Ada Hočevar Grom,
WHO minimum public health data set on prison health
Cannabis epidemic or return of opoid problems or decrease of high risk drug use among young adults in Austria Addictions Lisbon 2017, Paper Session 2 –
Reliability & validity issues in European web survey in Czech Republic
MODULE 2- EPIDEMIOLOGY OF DRUG USE IN THE AMERICAS
Mission Briefing on the World Drug Report 2012
Facebook ads as recruitment for online drug surveys: the Holy Grail?
Professor Paul I Dargan
World Drug Report 2018.
The social epidemiology of alcohol and drug use among Israeli school-aged children: Recent developments and current challenges Prof. Yossi Harel-Fisch.
The analysis of illicit drugs
New Psychoactive Substances (NPS) in Deep Web Marketplaces (DWM):
Research Methods Opinion Polls 11/13/2018
Results of an international drug testing service for cryptomarket users Mireia Ventura· ABD – Energy Control 15th May 2017.
Local Tobacco Control Profiles The webinar will start at 1pm
The European Experience: Prescription Drug Misuse in France, Germany, Italy and Spain 24 October 2017 Presented at Lisbon Addictions 2017 Jody L. Green,
Increased methadone dose reduces illicit drug injection among HIV negative methadone clients in Myanmar Sun Tun1,2, B. Vicknasingam2, Darshan Singh2 1.
Elena Gomes de Matos, Tessa-Virginia Hannemann,
Practical example of data triangulation to assess prevalence
Drug use among MSM (overview with focus on chemsex)
A comparison between North and South of Europe
Legalization of Drugs The Dutch experience.
Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender, Figure 1. National Drug Overdose Deaths—Number Among All Ages, by Gender,
Skopje, 21 November 2017, General Population Survey results– launch
STEPS Site Report.
Main pathological problems in the Czech Republic
Presentation transcript:

Comparison of data from WBE with other sources A summary of findings Been F., Lai F. Y., van Nuijs A. L. N., Covaci A.

Why would you want to compare? “Realising the full potential of wastewater-based information will depend on integrating it into the existing set of epidemiological indicators“ EMCDDA Insights 22; Assessing illicit drugs in wastewater: advances in wastewater-based drug epidemiology, 2016  “Realising the full potential of wastewater-based information will depend on integrating it into the existing set of epidemiological indicators“ EMCDDA Insights 22; Assessing illicit drugs in wastewater: advances in wastewater-based drug epidemiology, 2016 

Why would you want to compare? Measuring drug use General population surveys Deaths & Mortality Infectious diseases Problem drug use Treatment demand Law enforcement Wastewater-based epidemiology Measuring drug use General population surveys Deaths & Mortality Infectious diseases Problem drug use Treatment demand Law enforcement Wastewater-based epidemiology WBE is only one piece of the puzzle

Complementarity Surveys and other indicators Wastewater analysis Consumption Consumers Illicit drug loads [Milligrams per day per 1000 inhabitants] Prevalence Treatment Seizures …

International studies European multi-city study

International studies Cities across Europe 2011: 19 cities …. 2017: 50 cities Illicit drug loads [Milligrams per day per 1000 inhabitants] Prevalence At the time, the estimated illicit drug loads measured from wastewater analysis were compared to prevalence figures. In particular using data which was derived from the European Drug Report of 2012 and 2013.

International studies Cocaine Findings 2011-2013 Wastewater: stable use Other indicators: decline 2016 Wastewater: increased use European drug report: Increased availability (seizures) Stable prevalence Wastewater as an early warning of an upcoming surge in cocaine use? Looking at cocaine as an example, in 2013 WBE showed that consumption was overall stable Other indicators mentioned in the Eu Drug Report were on the other hand suggesting a decline. 3 years later, WBE results reported in the Eu Drug Report indicate that there had been an increase This appears to be confirmed by an increased availability, based on seizures, yet prevalence estimates indicate that consumption has remained stable. Looking at this data one might ask whether WBE (and seizures) are not suggesting a potential upcoming increase in COC use across europe

International studies Alcohol Wastewater 1 week, 2014, 20 cities Comparisons WHO: Global Status Report on Alcohol and Health Sales Surveys

International studies Alcohol Findings Wastewater: daily consumption higher for 11/20 cities compared to WHO Cities might be different than entire countries Longer sampling periods could potentially provide different results Interestingly, comparison of WBE results about alcohol use and figures from the WHO show that actual consumption appears to be higher to current figures in 11/22 cities across the world. However…

International studies Alcohol Findings Correlation with illicit drug use (from wastewater analysis)

National studies Italy Wastewater: 1 week, 2011-2014, 17 cities General population surveys (mail) 2010, 2012, 2014 NE, NW, Centre and S Stratified, 18-24y/25-34y/35-64y Last-month prevalence

National studies Italy Findings Overall WBE and GPS gave similar results Substance GPS [last month prevalence %] WBE [back-calculated consumption g/day 1000 inhab] Cannabis (THC) 3.0 4.35 (THC) Cocaine 0.43 0.78 Opioids 0.17 0.092 (Heroin) Amphetamines 0.14 0.103 (MA + MDMA) Time trends Period GPS [last month prevalence %] WBE [back-calculated consumption g/day 1000 inhab] 2010-2012 Amphetamines: -86% Opioids: -53% Cannabis: -39% Cocaine: -39% MA + MDMA: -87% Heroin: -29% Cannabis: +3% Cocaine: ND 2012-2014 Amphetamines: ND Opioids: ND Cannabis: +102% MA + MDMA: ND Heroin: ND Cannabis:+48%

National studies Finland Wastewater Complementary data 1, week, 14 cities, 2012 and 2014 Almost 40% of Finnish population Complementary data DUID statistics Seizures data Market size estimates

National studies Finland Findings Amphetamine dominates Confirmed increase by all indicators Increased purity in recent years Methamphetamine stable MDMA marked increase (WBE and DUID) Cocaine increasing popularity (all indicators)

Regional studies Mid-sized city – Switzerland Wastewater Two samples per week every second week 15 months (October ’13 – December ’14) Complementary data GPS (prevalence) Web-surveys (consumption habits) Purity (forensic) Surveys Forensic analysis Waste water Estimate cannabis use

Regional studies Mid-sized city – Switzerland Estimates Model Daily cannabis consumption [g.day-1.1000inhab-1] Number of users Prevalence (12 months) Epidemiological data only Estimate 8.1 11’830 6.2% 95% CI 3.8 - 13.8 7’078 – 16’860 5.3 - 7.1% Wastewater data only 17.2 - 5.0 - 51.3 Epidemiological and wastewater data 14.0 19010 9.4% 8.9 - 22.0 13’370 – 26’720 8.5 - 10.5% Model Daily cannabis consumption [g.day-1.1000inhab-1] Number of users Prevalence (12 months) Epidemiological data only Estimate 8.1 11’830 6.2% 95% CI 3.8 - 13.8 7’078 – 16’860 5.3 - 7.1% Model Daily cannabis consumption [g.day-1.1000inhab-1] Number of users Prevalence (12 months) Epidemiological data only Estimate 8.1 11’830 6.2% 95% CI 3.8 - 13.8 7’078 – 16’860 5.3 - 7.1% Wastewater data only 17.2 - 5.0 - 51.3

Conclusion WBE appears to anticipate results from GPS and other indicators  Early warning Provides more easily temporal and geographical information If a sufficient number of samples is collected Figures from other indicators are and remain vital

Conclusion Additional efforts are required Beyond comparisons with prevalence Develop interpretative frameworks including WBE and other indicators Prevalence Consumption habits User types Consumption estimates (WBE) … Uncertainties Inference approaches

Added value Corroborate/ confute Refine estimates Evaluate Policies Hypotheses Prevalence Prevention programs Trends Users Quantities Market size

Thank you